leisure time -WSS

leisure time

author：focus 2025-09-06 07:48:45 - browse：2

Transparent plastic divider on the reception desk in the hospital admission department with red lettering emergency. — Adobe

QuidelOrtho has recalled nearly 8,000 potentially faulty blood tests meant to help doctors quickly determine whether a patient is having a heart attack.

The tests inaccurately showed low levels of troponin, a protein that indicates damage to the heart. A false negative could lead doctors to mistakenly conclude their patient is not having a heart attack, delaying diagnosis or treatment when time is of the essence.

The device maker, which also sells products like the QuickVue Covid-19 antigen test, sent letters to health systems in May telling them to immediately stop using the test. The Food and Drug Administration classified the recall as serious, because problems with the product could result in serious injury or death. QuidelOrtho has reported 41 complaints, but no injuries or deaths so far.

The tests, which use either a blood or plasma sample, promise to return results in under half an hour. They are used in emergency rooms to triage patients suspected of having a heart attack.

Related: With Wegovy and Ozempic’s success, can device makers keep up in the race to treat obesity?

The FDA said the patients most at risk are those with zero or abnormal heart attack symptoms, for whom a diagnosis would be easy to miss without an accurate lab test.

The company advised using a different testing method to detect heart attacks. If none are available, doctors should be extra wary of the blood panel’s readings, perform multiple tests to confirm low troponin levels, and also reference data from EKGs and other imaging.

San Diego-based QuidelOrtho said the error is due to a “raw material issue” in its recall record. The issue caused the test to falsely pick up 30% less troponin than is present. The company did not respond to STAT’s request for more information on the error.

The test maker’s last serious recall was in 2021 for reports of false negatives from its Lyra PCR Covid-19 test when used with certain lab equipment. The notice impacted more than 18,000 test kits.

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Use wet bulb globe temperature, not heat index, to protect workers

focus

WSS

Making AI in medicine accessible to smaller, and rural hospitals

Free Covid tests will again be offered to all U.S. households

FDA weighs limits of animal data in assessing artificial wombs

Software glitch causes Tandem insulin pump to shutdown, FDA warns

Telehealth startups turn to complex chronic diseases

Steward Health Care files for bankruptcy

explore

leisure time

Related: With Wegovy and Ozempic’s success, can device makers keep up in the race to treat obesity?

entertainment

DIEP, the 'gold standard' of breast reconstruction, is under threat

Why the drug industry's warnings on the IRA's impact fall short

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Study: AI not yet building 'n

Psychedelics group wrestles with new pharma identity

FDA weighs limits of animal data in assessing artificial wombs

The high cost of giving birth even with insurance

Covid’s new normal has set in amid another rise in cases

Psychedelics group wrestles with new pharma identity

After gene therapy, two congenitally deaf children hear for the first time

leisure time

Medicare says breakthrough device reimbursement rule to come by summer

How to improve immunocompromised access to mAb treatments

Neurocrine congenital adrenal hyperplasia trial succeeds

FDA panel to weigh safety of artificial wombs for preterm births

Midwives could help bridge maternal health disparities in the U.S.

Study: People of West African ancestry at greater risk of cardiac amyloidosis

focus

explore

focus

leisure time